Navigation Links
Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate

PALO ALTO, Calif., Dec. 21, 2010 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Xyrem® (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy."  The new patent, number 7,851,506, is also listed in the FDA's Approved Drug Products List (the Orange Book).  

In addition to the newly issued patent, Xyrem is protected by seven other patents related to the product's formulation and Jazz Pharmaceuticals' distribution system.  Six issued patents are now listed in the Orange Book.  These patents expire from 2019 to 2024.

"Enhancing and enforcing the intellectual property coverage for Xyrem is an important strategic priority for our company," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, Jazz Pharmaceuticals' intent to vigorously enforce its intellectual property rights.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  Jazz Pharmaceuticals' actual results could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to protect its intellectual property and defend its patents, the possible introduction of generic products, the dependence of the company on sales of Xyrem, and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 5, 2010. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
2. MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
3. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
4. Lotus Pharmaceuticals Announces Change of Directors
5. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
6. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
7. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
8. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. John A. MacPhee Resigns From Strativa Pharmaceuticals
10. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
11. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Japanese therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... Doctors who missed a case of mesothelioma ... signs of mesothelioma and push for a diagnosis, especially in people exposed to asbestos. ... here to read it now. , Researchers at Gifu Prefectural Tajimi Hospital ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may ... one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there ... save the expense of having to replace NuvaRings more often than necessary. As such, ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved ... can help protect a patient’s overall health. The talk stressed the link between periodontal ...
(Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... to be a safe and convenient way to dispense prescription medications at home, ... safe and effective way to monitor and dispense prescription medications. In doing so, ...
(Date:11/27/2015)... ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating ... of 30 (see Table 1-1 ). More than 3.7 billion people under the ... virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . ...
Breaking Medicine News(10 mins):